Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Repligen Corporation - Common Stock (NQ:RGEN)

125.33 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Repligen Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
3 Out-of-Favor Stocks We Keep Off Our Radar
Hitting a new 52-week low can be a pivotal moment for any stock. These floors often mark either the beginning of a turnaround story or confirmation that a co... 
Via StockStory
News headline image
Q1 Rundown: Repligen (NASDAQ:RGEN) Vs Other Drug Development Inputs & Services Stocks
As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the drug development inputs & services ind... 
Via StockStory
News headline image
Why Repligen (RGEN) Stock Is Trading Up Today
What Happened? Shares of biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) jumped 2.9% in the afternoon session after RBC Capital resumed co... 
Via StockStory
Topics Artificial Intelligence Economy
News headline image
1 Growth Stock with Explosive Upside and 2 Facing Headwinds
Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived thr... 
Via StockStory
Repligen Corp (NASDAQ:RGEN) Sees Pre-Market Gain After Q1 Earnings Beat Offsets Slight Revenue Miss ↗
Via Chartmill
Topics Earnings
Repligen Corp (NASDAQ:RGEN) Stock Falls Despite Q4 Earnings Beat as 2026 Guidance Disappoints ↗
Via Chartmill
Topics Earnings
News headline image
Repligen, AdaptHealth, and IQVIA Stocks Trade Down, What You Need To Know
What Happened? A number of stocks fell in the afternoon session after the April PPI report showed wholesale inflation accelerating to 6% annually, with servi... 
Via StockStory
Topics Economy
News headline image
5 Revealing Analyst Questions From Repligen’s Q1 Earnings Call
Repligen’s first quarter results were met positively by the market, reflecting solid execution across core product lines and robust demand in both analytics ... 
Via StockStory
Topics Earnings
News headline image
3 Small-Cap Stocks We Steer Clear Of
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and... 
Via StockStory
News headline image
Repligen (RGEN) Shares Skyrocket, What You Need To Know
What Happened? Shares of biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) jumped 7.3% in the morning session after the company reported fir... 
Via StockStory
Topics Artificial Intelligence Earnings Regulatory Compliance
News headline image
Repligen (RGEN) Q1 2026 Earnings Call Transcript ↗
Repligen (RGEN) Q1 2026 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Repligen’s (NASDAQ:RGEN) Q1 CY2026 Sales Beat Estimates
Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) reported Q1 CY2026 results topping the market’s revenue expectations, with sales up 14.8% ... 
Via StockStory
Topics Earnings
News headline image
Repligen (RGEN) Q1 Earnings Report Preview: What To Look For
Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) will be announcing earnings results this Tuesday before the bell. Here’s what investors sh... 
Via StockStory
Topics Artificial Intelligence
News headline image
Why Repligen (RGEN) Shares Are Plunging Today
What Happened? Shares of biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) fell 5.3% in the afternoon session after an SEC filing revealed t... 
Via StockStory
Topics Economy Regulatory Compliance
News headline image
Envista, Baxter, Surgery Partners, Charles River Laboratories, and Repligen Stocks Trade Up, What You Need To Know
What Happened? A number of stocks jumped in the afternoon session after the reopening of the Strait of Hormuz signaled a cooling of global logistics and ener... 
Via StockStory
Topics Economy
News headline image
1 of Wall Street’s Favorite Stock to Own for Decades and 2 We Avoid
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remember... 
Via StockStory
News headline image
1 Cash-Producing Stock Worth Your Attention and 2 We Avoid
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff... 
Via StockStory
News headline image
RadNet, Evolent Health, Illumina, Charles River Laboratories, and Repligen Stocks Trade Down, What You Need To Know
What Happened? A number of stocks fell in the afternoon session after major indices including the S&P 500 and Dow Jones Industrial Average fell sharply as in... 
Via StockStory
Topics Economy Government Stocks
News headline image
1 High-Flying Stock with Solid Fundamentals and 2 We Avoid
"You get what you pay for" often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the ... 
Via StockStory
News headline image
1 Cash-Heavy Stock to Target This Week and 2 We Question
A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face c... 
Via StockStory
News headline image
A Look Back at Drug Development Inputs & Services Stocks’ Q4 Earnings: Repligen (NASDAQ:RGEN) Vs The Rest Of The Pack
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ... 
Via StockStory
News headline image
2 Growth Stocks Set to Flourishand 1 We Turn Down
Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived thr... 
Via StockStory
News headline image
3 Profitable Stocks We Keep Off Our Radar
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does... 
Via StockStory
Brown Capital Dumps 190,000 AppFolio Shares Worth $45.1 Million ↗
Via The Motley Fool
News headline image
AMN Healthcare Services, RadNet, Evolent Health, Repligen, and Amphastar Pharmaceuticals Stocks Trade Down, What You Need To Know
Via StockStory
Topics Economy
News headline image
3 Healthcare Stocks We’re Skeptical Of
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have not only reali... 
Via StockStory
News headline image
3 Reasons to Avoid RGEN and 1 Stock to Buy Instead
Repligen trades at $124.97 and has moved in lockstep with the market. Its shares have returned 7.6% over the last six months while the S&P 500 has gained 6.6... 
Via StockStory
Topics Stocks Supply Chain
News headline image
Privia Health, Repligen, and RadNet Shares Plummet, What You Need To Know
A number of stocks fell in the afternoon session after a surprisingly hot wholesale inflation report fueled investor concerns about persistent price pressures. 
Via StockStory
Topics Economy Stocks
News headline image
Repligen (RGEN) Q4 2025 Earnings Call Transcript ↗
Repligen (RGEN) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings World Trade
News headline image
Repligen (NASDAQ:RGEN) Exceeds Q4 CY2025 Expectations
Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) reported Q4 CY2025 results exceeding the market’s revenue expectations, with sales up 18.1% year on year to $197.9 million. The... 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.